We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Proximagen Grp | LSE:PRX | London | Ordinary Share | GB00B06FMX57 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 365.25 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 365.25 | GBX |
Proximagen Neuroscience (PRX) Share Charts1 Year Proximagen Neuroscience Chart |
|
1 Month Proximagen Neuroscience Chart |
Intraday Proximagen Neuroscience Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 02/9/2021 | 08:37 | Prosus NV - Tech Investment Company | 2 |
| 01/4/2016 | 21:49 | Proximagen first thread | 66 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 02/9/2021 08:30 by haroldthegreat Thank you Tim . I used the wrong code ! Why no price on left side of chart ? |
Posted at 01/4/2016 21:49 by elgordo For my own reference more than anything else -Most Recent Events 15 Feb 2016 Phase-II development in Osteoarthritis is ongoing in United Kingdom (PO) 01 Dec 2015 PRX 167700 licensed to Roche worldwide 19 Jul 2013 Phase-II clinical trials in Osteoarthritis in United Kingdom (PO) |
Posted at 22/7/2015 14:35 by elgordo In case anyone out there is interested...I have just got hold of the CVR Representative’ In summary, the potential value from the CVRs was derived from two programmes, and their status is as follows: PRX00993 – dead and buried (“discontinued PRX-167700 – Active partnering discussions on back of progress and headline results of Phase IIa osteoarthritis study and planning for IBD clinical studies. “In January 2015 a potential partner proposed terms for supporting Phase II clinical study with an option for commercial rights. Discussions are continuing with this potential partner as well as other potential partners.” So, still some hope of value to be derived from the CVRs, though I believe they expire at the end of August 2017 so time is starting to run quite short. |
Posted at 19/6/2012 13:15 by elgordo A great result. Any other holders out there with thoughts on whether better to sell into the market, or take the 320p and the CVRs? Should have a good few weeks to decide, and the implied value of the CVRs appears to be creeping upwards... I'm minded to gamble that Upsher-Smith's confidence in acquiring the VAP-1 and PRX00933 programs will convert into successful commercialisation down the line, but if the share price moves up further there will be a point where it becomes clearly better to take the money now. What I have no way of assessing is where that point lies. |
Posted at 22/12/2010 12:27 by mike111d Yes well done to the BOD, another good year for PRX. |
Posted at 05/1/2010 10:44 by elgordo Looks like I was wrong about this board "livening up" once PRX announced an acquisition. Admittedly a small deal (and, as far as I can figure, not at a significant premium to MDM's cash balances - £4.3m v £3.5m), but nice to see some activity here. |
Posted at 04/11/2009 20:30 by elgordo Wow, it really is quiet here, isn't it? Clearly the CBT acquisition was too minor to attract any interest. I guess things will liven up when PRX announces its first major acquisition using some of its £50m war chest. |
Posted at 05/12/2008 10:47 by promethean Posted this on stockopedia... FYI - doesn't seem like any PI's have picked up on Proximagen yet... The latest surge above 140p has coincided with some unified director buying. Admittedly the size of the trades is pretty small... e.g. the Chairman only bought a few grands worth... although non-exec RD Ashton bought about 30k's worth from scratch. And the FD bought his first 5k worth. 5 directors bought together... I wonder whether 4 of them decided to pick up some more while Ashton built an initial stake... I always find these titchy directors purchases rather peculiar, but in spite of that it has to be taken as a good sign. Ashton is by all accounts the former CEO of SkyePharma and hardly lacking a bob or tow. Things are going well for Proximagen at present though, so I guess we should take these dealings as positive. It certainly is in stark contrast to the huge offloading of shares going on at Abcam which has a similarly buoyant share price. |
Posted at 14/7/2008 07:32 by charmer1_23 RNS Number : 9598YProximagen Neuroscience Plc 14 July 2008 For immediate release 14 July 2008 PROXIMAGEN NEUROSCIENCE PLC ('Proximagen' or 'the Company') PROXIMAGEN SIGNS $232 MILLION LICENSING AGREEMENT WITH UPSHER-SMITH TO DEVELOP PRX1 PROGRAMME $6 MILLION EQUITY INVESTMENT IN PROXIMAGEN AT c.200 PENCE PER SHARE BY UPSHER-SMITH ~ Upfront payment, milestone payments totalling up to $232 million payable to Proximagen ~ ~ Royalties payable to Proximagen on worldwide sales ~ London, UK - Proximagen Neuroscience plc (AIM: PRX), the drug discovery and development company focused on neurodegenerative diseases, is today pleased to announce it has entered into a worldwide licensing agreement ('the Agreement') with Upsher-Smith Laboratories Inc. ('Upsher-Smith'), the Minnesota-based company which develops, manufactures and markets pharmaceuticals in a number of therapeutic areas. The Agreement covers the development and commercialisation of Proximagen's proprietary PRX1 programme for the symptomatic treatment of Parkinson's disease (PD). Proximagen will receive an upfront payment and milestone payments totalling up to $232 million (£117 million*), plus royalties on global product sales. Highlights of the Agreement: Upsher-Smith will pay Proximagen an upfront payment and milestone payments totalling up to $232 million (£117 million*) upon the PRX1 programme reaching certain development and sales milestones; According to the terms of the Agreement, Upsher-Smith expects to make a $6 million (£3.03 million*) equity investment in Proximagen at c.200 pence per share, a premium of c.100% to the closing share price of Proximagen on Friday 11 July 2008; Upon this first equity investment, Upsher-Smith will hold 7.1% of the enlarged issued share capital of Proximagen; Under the terms of the Agreement, Proximagen is entitled to up to double-digit royalties on global product sales on an escalating royalty basis; and Upsher-Smith will be responsible for the worldwide development and commercialisation of PRX1 under the direction of a joint steering committee on which there will be representation from Proximagen. Upsher-Smith Upsher-Smith is an established and rapidly growing, privately-held company based in Minneapolis, Minnesota. It is a fully integrated pharmaceutical company with expertise in product development, formulations research, clinical research, pharmacovigilance, manufacturing, marketing and sales, as well as legal, regulatory affairs and quality assurance. Upsher-Smith's core focus has traditionally been on developing branded and generic products in the therapeutic areas of women's health, dermatology, cardiology and neurology, and the Agreement demonstrates Upsher-Smith's strategic intent to broaden its pipeline in disorders of the central nervous system. PRX1 - Meeting a high unmet market need Proximagen's PRX1 programme, which is currently in the pre-clinical stage of development, has been designed to provide a 'super' version of L-DOPA, the current gold-standard treatment for PD, to overcome the problems associated with the current treatment of PD. The results from the PRX1 development programme are deemed by scientific experts to be highly significant and the drug candidate has the potential to become the drug of first choice for addressing motor symptoms associated with PD. The worldwide market for PD therapeutics is estimated to be valued at more than $2.5 billion per annum (source: IMS Health). The PRX1 drug candidate has shown significantly increased biological half-life (the period of time required for the concentration or amount of drug in the body to be reduced by one-half) in pre-clinical studies compared with L-DOPA. This could represent a significant advancement in the current treatment of patients, since the existing L-DOPA controlled release preparations increase the half-life of L-DOPA by less than two hours. By increasing the plasma half-life in patients, the desired effect of Proximagen's drug candidate, compared to the traditional L-DOPA, would be to reduce the peak and trough blood levels associated with involuntary movements in PD, reduce the number of daily doses needed and thereby improve patients' sleep and general quality of life. Furthermore, in pre-clinical studies, the administration of the PRX1 drug candidate at dose equivalents to L-DOPA produced maximal reversal of motor disability with virtually no dyskinesia side effects. Commenting on the Agreement, Kenneth Mulvany, CEO of Proximagen Neuroscience plc, said: 'We are delighted to have partnered our PRX1 programme with Upsher-Smith, a company whose ambitions for meeting the needs of Parkinson's disease patients match our own and whose excellence in clinical development and commercialistion complements Proximagen's expertise in research and development. We are confident that the two companies will make excellent partners, and together, we look forward to maximising the potential of this exciting programme. 'This deal demonstrates Proximagen's ability to leverage our expertise in Parkinson's disease to discover first class drug candidates, as well as our ability to commercialise early stage products. 'Proximagen already has a strong cash balance and is now very well positioned to continue investment in its pipeline and exploit commercial opportunities as they arise to continue building value for shareholders.' Tom Burke, Executive Vice President Commercial Operations for Upsher-Smith, added: 'PRX1 is a novel pharmaceutical drug candidate that we believe could become a leader in the treatment of Parkinson's disease. We are excited by the potential market opportunity and the profile of the PRX1 programme drug candidate. We are also delighted to be working with Proximagen, a company with world class expertise in the field of Parkinson's disease. 'Upsher-Smith's strength in the development and commercialisation of pharmaceutical products will enable us to successfully take the PRX1 programme to the next stage of development and beyond. There is a clear unmet medical need for the treatment of Parkinson's disease and we look forward to the successful development of PRX1.' * Exchange rate used: £1=$1.98 For further information, please contact: Proximagen Neuroscience plc Tel: 020 7848 6938 Kenneth Mulvany, Chief Executive James Hunter, Finance Director Buchanan Communications Tel: 020 7466 5000 Mary-Jane Johnson, Tim Anderson, Catherine Breen Canaccord Adams Limited (NOMAD) Tel: 020 7050 6500 Mark Williams, Adria Da Breo-Richards About Proximagen Proximagen is a drug discovery and development company that is primarily focused on the identification and subsequent out-licensing of novel therapeutics to improve the quality of life for patients suffering from neurodegenerative disease such as Parkinson's disease and Alzheimer's disease. Proximagen is building a development pipeline to address the significant medical needs of these patients and has made substantial progress in five proprietary programmes. Proximagen anticipates out-licensing its programmes at early stages up to and including Phase II proof of concept studies and commercialising carefully selected in-licensed and collaborative programmes. Proximagen joined the AIM market of the London Stock Exchange in March 2005. For more information please visit the Company's web site: www.proximagen.com. About Upsher-Smith Upsher-Smith is pursuing improved drug therapies to improve people's lives. The evolution of our company is driven by the ever-changing needs of patients, physicians, pharmacists, and healthcare organizations. Our perspective is not 'more products,' but the right products that make people's lives better. At every level of our business, we are driven to be the best. Upsher-Smith Laboratories is focused on market expansion in women's health, dermatology, and cardiology, in addition to developing products for neurology. Our most valuable resources are the people who create and innovate products to support healthcare professionals. For more information, please visit Upsher-Smith's website at www.upsher-smith.com This information is provided by RNS The company news service from the London Stock Exchange END AGREAEXDFSEPEAE |
Posted at 15/5/2007 21:40 by sicilian_kan I'm surprised no one has commented on this share since 2005. Any views on the following?Publication: Scrip World Pharmaceutical News Date: 7 March 2007 Words: 631 Proximagen reveals promising alternative to L-DOPA for Parkinson's disease Proximagen Proximagen Neuroscience has ended the fiscal year with positive preclinical data for PRX1, a series of prodrug candidates for the symptomatic treatment of Parkinson's disease. The project was conceived as an improved L-DOPA, the "gold standard" for the alleviation of Parkinson's disease symptoms, accounting for 70% of the prescription market. Professor Peter Jenner, Proximagen's founder and chief science officer, noted that there had not been any attempts to improve L-DOPA's shortcomings. Generic forms of the drug replicate its instability - a short half-life (3-4 hours), and peak and trough blood levels which provoke dyskinesia and bradykinesia in patients. The PRXl programme produced four advanced lead candidates. Preclinical studies have shown that one of these, PRXl157, has a biological half-life of 6-8 hours, and provides more stable and constant plasma levels. The company is in the process of determining dosage requirements, and plans to file an IND later this year. It expects to see the compound start clinical trials next year, and hopes that it will eventually compete with Duodopa, an intraduodenal infusion of carbidopa and levodopa developed by Neopharma (now part of Solvay) for the treatment of late-stage Parkinson's disease. Professor Jenner says Duodopa costs £27,000 per year per patient, and he hopes that the PRXl series will provide a cheaper but just as effective alternative. ...other projects The company has three other neurodegenerative projects in its pipeline. PRX2, for the inhibition of L-DOPA-induced dyskinesia, was advanced by licensing in drug candidates from Northwestern University, US, last May. Preclinical studies have suggested that the same mechanism of action as the licensed molecules could also be effective in the treatment of depression and pain. Proximagen's PRX4 programme, which Professor Jenner described as the classical biotech long-term high-risk project, aims to confer neuroprotection in an increasingly elderly population. PRX4 derivatives have been found to inhibit neurodegeneration in neuronal cells. The PRX5 programme has revealed a series of novel compounds that target cognitive decline, common to around 10% of people aged 60 and over. This year Proximagen hopes to characterise orally active drug candidates which halt cognitive decline in Parkinson's and Alzheimer's diseases as well as other dementing illnesses. The company is already planning to increase the therapeutic scope of its projects, in the direction of pain, cognition, depression and anxiety. For the full year ending last November, the company had a turnover of £737,509, compared with £878,310 for the previous year. This was composed of revenue from its fee-for-service business, which provides some financial support to its R8D programmes. Service contracts are already in place with GlaxoSmithKline, Novartis, Boehringer Ingelheim, Roche, Orion, Lundbeck, Neurocrine Biosciences, Schwarz Pharma, Elbion, Lilly, Fujimoto, Shire and Kyowa. Proximagen believes that these relationships not only increase its market intelligence but will act as a conduit to future licensing out of proprietary programmes. The company's pretax losses widened on a sharp increase in spending. Thanks to a tax credit Proximagen made a small, £4,612 (0.3 pence per share) net profit in fiscal 2005, but last year showed a net loss of £1.6 million, or 8 pence per share. There was a fivefold increase in R8D spending this year to £1.74 million. There was also a considerable difference in administrative expenses incurred a 36% jump to £860.818. James Hunter, the finance director, explained that this was due to costs associated with being a publicly listed company for the entire year, as opposed to only eight out of twelve months the previous year, a rise in headcount from 12 to 19 and legal costs associated with intellectual property protection. Proximagen also drew attention to its cash position, which stood at £11.5 million at the end of the fiscal vear, down from £13 million at the end of 2005. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
